Dengue’s Downfall?

Researchers characterize a protein that could be key to the virus’s virulence—and to developing a vaccine against the mosquito-borne disease.

By | September 15, 2015

Female Aedes aegypti mosquitoWIKIMEDIA, JAMES GATHANYA dengue virus protein called nonstructural protein 1 (NS1) elicits proinflammatory immune responses in infected hosts, resulting in leakage out of capillaries and other blood vessels, according to two studies published last week (September 9) in Science Translational Medicine. But vaccination with NS1 or treatment with NS1-targeting monoclonal antibodies protected mice against these pathogenic effects, according to one of the studies.

In the early 2000s, Paul Young of the University of Queensland, Australia, and his colleagues found that circulating levels of NS1 correlated with the development of severe illness. “If patients had high levels of NS1, they were more likely to go on to severe disease,” Young told Smithsonian. “We thought it was just a viral infection marker, but then we asked if it was having a direct effect itself.”

Upon closer examination of NS1’s function, Young’s team found that it binds toll-like receptor 4 (TLR4), which then allows the protein to attach to the endothelial cells of blood vessel walls and causes them to leak. NS1 also stimulated the release of proinflammatory cytokines. In essence, NS1 triggered immune responses like those elicited by bacterial toxins. As a result, Young told The Guardian, existing drugs to treat sepsis—an overzealous immune response to bacterial infection—might also be effective in treating dengue.

Meanwhile, Eva Harris of the University of California, Berkeley, and colleagues provided evidence that vaccinating with NS1 itself could also combat the virus. Treating mice with a small amount of the protein, Harris and her team found that the animals developed antibodies and were subsequently protected from the virus. NS1 even provided some protection against the four different strains of dengue. Vaccinating with NS1 from DENV2, for example, provided 100 percent protection against that strain, as well as 75 percent against DENV1 and 60 percent against DENV3 and DENV4. 

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech